Try our beta test site
132 studies found for:    Kaiser Permanente | Open Studies | cancer
Show Display Options
Rank Status Study
21 Recruiting S1417 CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
Conditions: Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
22 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
23 Recruiting MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
Interventions: Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
24 Recruiting FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
25 Recruiting Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: cetuximab;   Radiation: intensity-modulated radiation therapy
26 Recruiting Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
27 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
28 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
29 Recruiting Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Conditions: Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
30 Recruiting S0820, Adenoma and Second Primary Prevention Trial
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
31 Recruiting Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fulvestrant;   Drug: anastrozole
32 Recruiting A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Trastuzumab Emtansine;   Drug: Capecitabine
33 Recruiting Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance
Conditions: BRCA1 Mutation;   BRCA2 Mutation;   Atypia Suspicious for Malignancy
Intervention: Device: MAKO 7
34 Recruiting Breast Cancer WEight Loss Study (BWEL Study)
Condition: Breast Carcinoma
Interventions: Other: Health Education Program;   Other: Weight Loss Intervention
35 Recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IB Squamous Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIA Squamous Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIB Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Squamous Cell Lung Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
36 Recruiting S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Biological: Rilotumumab;   Drug: Taselisib
37 Recruiting Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer;   Stage II Vaginal Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Vaginal Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Vaginal Cancer
Interventions: Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
38 Recruiting Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
39 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive Side Effects of Cancer Therapy;   Psychological Impact of Cancer;   Radiation Toxicity;   Sexual Dysfunction and Infertility;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
40 Recruiting S1400I Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.